Stockscreener 앱 받기
17.01
1.22%
-0.21
시간 외 거래:
17.01
전일 마감가:
$17.22
열려 있는:
$17.22
하루 거래량:
301.90K
Relative Volume:
1.34
시가총액:
$771.80M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.13%
1개월 성능:
-8.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$16.55
$17.41
1주일 범위
$15.58
$18.25
52주 변동 폭
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
MPLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
17.01 | 781.32M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-21 | 개시 | Jefferies | Buy |
| 2025-11-21 | 개시 | Leerink Partners | Outperform |
| 2025-11-21 | 개시 | Morgan Stanley | Overweight |
| 2025-11-21 | 개시 | Stifel | Buy |
Maplight Therapeutics Inc 주식(MPLT)의 최신 뉴스
Maplight Therapeutics (MPLT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
FDA grants fast track designation to MapLight’s Alzheimer’s drug By Investing.com - Investing.com India
MapLight Therapeutics' Alzheimer's Psychosis Drug Granted FDA Fast Track Status - Nasdaq
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis - The Manila Times
MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN
What is the current Price Target and Forecast for MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors - TipRanks
MapLight Therapeutics Earnings Notes - Trefis
MapLight Therapeutics advances CNS drug pipeline - MSN
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors - TipRanks
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - whbl.com
MapLight2025 Funding Rounds & List of Investors - Tracxn
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to Russell 2000 Growth Index - marketscreener.com
SandboxAQ and MapLight join forces on CNS - The Pharma Letter
6 Biotechs That Could Be Big Pharma’s Next M&A Target - BioSpace
SandboxAQ and MapLight Therapeutics Partner on Novel CNS Therapies - HPCwire
SandboxAQ and MapLight form $200 million CNS drug discovery alliance By Investing.com - Investing.com Nigeria
SandboxAQ and MapLight form $200 million CNS drug discovery alliance - Investing.com
MapLight links up with SandboxAQ to pursue AI-discovered CNS treatments - Axios
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies - The Manila Times
Sandboxaq And Maplight Therapeutics Announce Collaboration To Discover And Develop Novel CNS Therapies - TradingView — Track All Markets
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
MapLight Therapeutics completes IPO and raises $296.5M - MSN
Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (MPLT) and Halozyme (HALO) - The Globe and Mail
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Adversity is less terrifying than hope: MapLight Therapeutics Inc (MPLT) - setenews.com
MapLight Therapeutics Advances CNS Drug Pipeline - TipRanks
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Maplight Therapeutics (MPLT) Earnings Date and Reports 2026 - MarketBeat
Maplight Therapeutics reports third quarter financial results - marketscreener.com
MapLight Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
MapLight Therapeutics Completes IPO and Raises $296.5M - TipRanks
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress - The Manila Times
MapLight Therapeutics, Inc. SEC 10-Q Report - TradingView
MPLT: Clinical pipeline advances and robust IPO funding position operations through 2027 - TradingView — Track All Markets
Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts - TipRanks
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug - Investing.com Canada
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - Benzinga
SETIA VISHWAS Insider Trades - Nasdaq
MapLight Therapeutics (MPLT) Stock Analysis Report | Financials & Insights - Benzinga
MPLT Interactive Stock Chart | MapLight Therapeutics, Inc. Stock - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
MapLight Therapeutics Closes Successful IPO and Private Placement - MSN
Maplight Therapeutics Inc (MPLT) 재무 분석
Maplight Therapeutics Inc (MPLT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Maplight Therapeutics Inc 주식 (MPLT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Catalyst4, Inc. | 10% Owner |
Oct 28 '25 |
Buy |
17.00 |
5,441,176 |
92,499,992 |
19,697,464 |
2.52%
0.07%
자본화:
|
볼륨(24시간):